<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03218111</url>
  </required_header>
  <id_info>
    <org_study_id>1609017536</org_study_id>
    <nct_id>NCT03218111</nct_id>
  </id_info>
  <brief_title>Glymphatic Kinetics In Healthy Adult Volunteers</brief_title>
  <official_title>Evaluation Of Brain Glymphatic Kinetics Following Intrathecal Administration Of Gadolinium In Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done in order to see how gadolinium-based MRI contrast (Magnevist)&#xD;
      travels through the central nervous system (CNS) when injected through the spinal column, and&#xD;
      to compare differences between two age groups (age 20-50, and 51-80). This will allow&#xD;
      investigators to evaluate how much contrast has crossed into the tissue surrounding the&#xD;
      brain. Such information will help investigators determine whether this kind of contrast can&#xD;
      be used to model how other drugs might travel through the CNS and evaluate its use as an&#xD;
      illustrative imaging marker that mirrors the glymphatic system.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, longitudinal study of MR imaging of intrathecally delivered gadolinium&#xD;
      contrast (Magnevist, Gd-DTPA) in healthy adult male and female subjects. Subjects will be&#xD;
      divided into two groups (20-50 years old and 51-80 years old) both of which will receive&#xD;
      intrathecal injection of the drug Magnevist (Gd-DTPA), followed by serial MR imaging over the&#xD;
      course of 10-12 hours. The purpose of the study is determine the transport kinetics of&#xD;
      Central Nervous System (CNS) exposure to gadolinium contrast injected into the lumbar&#xD;
      intrathecal space (lower back) and evaluate changes with age. This will allow investigators&#xD;
      to evaluate the brain parenchymal penetration of gadolinium as an illustrative imaging marker&#xD;
      that mirrors the glymphatic system. Investigators hypothesize the exposure and penetration&#xD;
      patterns of the neuraxis to neurotherapeutic drugs can be modeled using gadolinium&#xD;
      intrathecal contrast administered in the lumbar intrathecal space.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 6, 2017</start_date>
  <completion_date type="Actual">February 8, 2018</completion_date>
  <primary_completion_date type="Actual">February 6, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Drug distribution over time</measure>
    <time_frame>6 time-points over 12 hours</time_frame>
    <description>The drug distribution of gadolinium contrast throughout the Central Nervous System over time (12 hours)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Healthy Normal Subjects</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Healthy normal subjects 20-80 years old. All subjects will undergo the same procedures: intrathecal injection, using CT-guidance, with an MRI contrast. After injection subjects will undergo six sessions of MR imaging over a 10-12 hour period</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MR Imaging</intervention_name>
    <description>All subjects will undergo six sessions of MR imaging over a 10-12 hour period</description>
    <arm_group_label>Healthy Normal Subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CT-guidance</intervention_name>
    <description>All subjects will be injected, intrathecally using CT-guidance, with an MRI contrast.</description>
    <arm_group_label>Healthy Normal Subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Deemed healthy and able to undergo MR imaging by the Site Investigator, based on&#xD;
             screening assessments:&#xD;
&#xD;
             medical history, physical examination, vital signs, and clinical laboratory values&#xD;
&#xD;
          2. Age 20-80&#xD;
&#xD;
          3. Willing to undergo multiple imaging sessions&#xD;
&#xD;
          4. Normal screening MRI to exclude subjects with a mass (e.g., disk herniation),&#xD;
             congenital malformation (e.g., Chiari malformation), or an abnormal curvature of the&#xD;
             spine that could alter CSF flow.&#xD;
&#xD;
          5. If female of childbearing age: negative pregnancy test&#xD;
&#xD;
          6. Normal Basic metabolic Panel and CBC (Platelet count &gt; 150,000; Hb &gt;8)&#xD;
&#xD;
          7. Willing to undergo LP procedure. -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Kyphosis&#xD;
&#xD;
          2. Claustrophobia&#xD;
&#xD;
          3. Chronic cough&#xD;
&#xD;
          4. Active infection with fever (&gt;101.5), to limit risk of meningitis. Infections could&#xD;
             include pneumonia, pharyngitis, skin infection, UTI, etc.&#xD;
&#xD;
          5. History of CNS tumor or anomaly&#xD;
&#xD;
          6. History of radiation therapy to the CNS&#xD;
&#xD;
          7. History of hydrocephalus&#xD;
&#xD;
          8. Abnormality on MRI that could impede CSF flow (i.e., extruded disk)&#xD;
&#xD;
          9. Laboratory finding of prolonged coagulation times&#xD;
&#xD;
         10. Pregnant/nursing&#xD;
&#xD;
         11. Prior spine or brain surgery or trauma&#xD;
&#xD;
         12. Inability to lay still and supine&#xD;
&#xD;
         13. Recent lumbar puncture within 1 month of planned LP.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J. Levi Chazen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>July 7, 2017</study_first_submitted>
  <study_first_submitted_qc>July 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2017</study_first_posted>
  <last_update_submitted>February 9, 2018</last_update_submitted>
  <last_update_submitted_qc>February 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glymphatic network</keyword>
  <keyword>healthy</keyword>
  <keyword>central nervous system</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No Current Plan</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

